This double-blind, placebo-controlled crossover trial (n=16) investigates whether pretreatment with memantine can prevent the memory impairment typically caused by MDMA in recreational users.
Led by Maastricht University, the study aims to assess memory performance using verbal and prospective memory tests, with event-related potentials measured during the verbal memory task.
Memantine, a drug used in Alzheimer’s treatment, will be administered two hours before MDMA or placebo. The study, employing a 4-way crossover design, anticipates enrolment to begin in April 2011 and seems to have been completed (but the study record not updated).
You can find the results of the study here.
Topic Safety
Healthy Subjects
Compound MDMA
Country Netherlands
Visit trial
Status
Completed
Results Published
Yes
Start date
01 April 2011
End date
01 January 2012
Phase
Not Applicable
Design
Blinded
Type
Interventional
Generation
First
Participants
16
Sex
All
Age
18- 40
Therapy
No
Trial Details
This double-blind trial (n=16) led by Maastricht University aims to determine if memantine can prevent MDMA-induced memory impairment in recreational users. Participants will receive memantine or placebo before MDMA, with memory performance assessed through verbal and prospective memory tests. The study, pending recruitment, adopts a 4-way crossover design, anticipating enrolment to start in April 2011.NCT Number NL2664
Sponsors & Collaborators
Maastricht UniversityMaastricht University is host to the psychopharmacology department (Psychopharmacology in Maastricht) where various researchers are investigating the effects of psychedelics.